Mélanome uvéal et tumeurs oculaires CLXS196X2101 A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma Paris SOPHIE PIPERNO-NEUMANN
Phases précoces tumeurs solides CPDR001X2103 Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib). Paris
Phases précoces tumeurs solides DRIIV-1 (OX2016 -203-01) An open-label, dose-escalation phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors. Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides M15-819 A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Gynécologie - Col utérus NiCOL (IC 2016-08) A phase-I study of nivolumab in association with radiotherapy and cisplatin in locally advanced cervical cancers followed by adjuvant nivolumab for up to 6 months Paris, Saint-Cloud MANUEL RODRIGUES
Sein RadioPARP A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease Paris
Appareil pulmonaire BI 1336-0011 An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With BI 754091 to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Check Point Inhibitor naïve Patient With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Progressed During or After First Line Platinum-based Treatment. Paris NICOLAS GIRARD
Sein métastatique triple négatif CO40151 A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer Paris
Phases précoces tumeurs solides INDUCE-1 (GSK-204691) A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides MK4621-002 A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors Paris